LOGIN  |  REGISTER

Spok Sets Date to Report Third Quarter 2023 Results

October 19, 2023 | Last Trade: US$13.90 0.07 0.51

ALEXANDRIA, Va. / Oct 19, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its third quarter 2023 operating results on Wednesday, October 25, 2023, after the close of the U.S. financial markets.

Management will host a conference call and webcast to discuss these financial results on Thursday, October 26, 2023, at 9:00 a.m. ET. The presentation is open to all interested parties and may include forward-looking information.

Conference Call Details

Date/Time

Thursday, October 26, 2023, at 9:00 a.m. ET

Webcast:

https://www.webcast-eqs.com/register/spok_q32023_en/en

U.S. Toll-Free Dial In:

877-407-0890

International Dial In:

+1-201-389-0918

To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on Spok Care Connect® platforms to enhance workflows for clinicians and support administrative compliance. Our customers send over 100 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com or follow @spoktweets on Twitter.

Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

Terns Pharmaceuticals

Stock Quote

Last Trade: US$13.90
Daily Change: 0.07 0.51
Daily Volume: 98,708
Market Cap: US$286.340M

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page